Galapagos (GB:0JXZ) has released an update.
Galapagos NV has reported promising results for their CD19 CAR-T cell therapy, GLPG5101, in treating relapsed/refractory non-Hodgkin lymphoma, with high complete response rates observed in a phase 1/2 study. The company highlighted the innovative decentralized T-cell production platform that enables quick delivery of fresh CAR-T cells within seven days. These findings, demonstrating both safety and efficacy, will be presented at the European Hematology Association’s 2024 congress.
For further insights into GB:0JXZ stock, check out TipRanks’ Stock Analysis page.
